Concourse Financial Group Securities, Inc. Mi Nk Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q1 2025

14 transactions

Quarter	Operation	Price Per share
Q4 2024 Feb 13, 2025	BUY	$0.46 - $0.79 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$0.74 - $1.14 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$0.87 - $1.56 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.84 - $1.12 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.88 - $1.21 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.1 - $2.09 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.1 - $2.09 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.89 - $3.33 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.9 - $2.48 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.89 - $3.16 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.19 - $3.4 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.25 - $3.25 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.2 - $4.75 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.12 - $20.03 $0 - $0

Others Institutions Holding INKT

# of Institutions

Shares Held

106K

Call Options Held

Put Options Held

View Full List

About MiNK Therapeutics, Inc.

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $689M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

More about INKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account